[HTML][HTML] Patients double-seropositive for ANCA and anti-GBM antibodies have varied renal survival, frequency of relapse, and outcomes compared to single …

SP McAdoo, A Tanna, Z Hrušková, L Holm, M Weiner… - Kidney international, 2017 - Elsevier
Co-presentation with both ANCA and anti-GBM antibodies is thought to be relatively rare.
Current studies of such ‘double-positive’ cases report small numbers and variable outcomes. …

Long-term follow-up of a combined rituximab and cyclophosphamide regimen in renal anti-neutrophil cytoplasm antibody-associated vasculitis

…, S Gopaluni, A Tanna… - Nephrology Dialysis …, 2019 - academic.oup.com
Background Current guidelines advise that rituximab or cyclophosphamide should be used
for the treatment of organ-threatening disease in anti-neutrophil cytoplasm antibody (ANCA)-…

Long-term outcome of anti-neutrophil cytoplasm antibody-associated glomerulonephritis: evaluation of the international histological classification and other prognostic …

A Tanna, L Guarino, FWK Tam… - Nephrology Dialysis …, 2015 - academic.oup.com
Background Anti-neutrophil cytoplasm antibody (ANCA) associated vasculitis with renal
involvement requires treatment with potentially toxic drugs to reduce morbidity and mortality, and …

Outcome and treatment of elderly patients with ANCA-associated vasculitis

…, AJ Mohammad, Z Hruskova, A Tanna… - Clinical journal of the …, 2015 - journals.lww.com
Results Median follow-up was 730 days (interquartile range, 244–730). Overall 1-year
survival was 71.5% and 2-year survival was 64.6%. Older age, higher creatinine, and lower …

[HTML][HTML] Use of the HoloLens2 mixed reality headset for protecting health care workers during the COVID-19 pandemic: prospective, observational evaluation

…, S Purkayastha, A Sivananthan, A Tanna… - Journal of medical …, 2020 - jmir.org
Background The coronavirus disease (COVID-19) pandemic has led to rapid acceleration in
the deployment of new digital technologies to improve both accessibility to and quality of …

Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis

SK Todd, RJ Pepper, J Draibe, A Tanna… - …, 2014 - academic.oup.com
Objectives. B cells are central to the pathology of ANCA-associated vasculitis (AAV), a
disease characterized by autoantibodies and effectively treated by rituximab. In addition to …

[HTML][HTML] Combination treatment with rituximab, low-dose cyclophosphamide and plasma exchange for severe antineutrophil cytoplasmic antibody-associated …

…, J Galliford, M Griffith, JB Levy, FWK Tam, A Tanna… - Kidney International, 2021 - Elsevier
Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis can present with life-threatening
lung-kidney syndromes. However, many controlled treatment trials excluded patients …

Long-term outcome in biopsy-proven acute interstitial nephritis treated with steroids

M Prendecki, A Tanna, AD Salama… - Clinical Kidney …, 2017 - academic.oup.com
Background: There are no prospective randomized controlled trials describing the outcome
of acute interstitial nephritis (AIN) treated with steroids, and retrospective studies are limited. …

Long-term outcomes of rituximab therapy in ocular granulomatosis with polyangiitis: impact on localized and nonlocalized disease

L Joshi, A Tanna, SP McAdoo, N Medjeral-Thomas… - Ophthalmology, 2015 - Elsevier
… Author links open overlay panel Lavnish Joshi MD, FRCOphth 1 2 , Anisha Tanna MBBS,
MRCP 2 3 , Stephen P. McAdoo MBBS, MRCP 2 3 , Nicholas Medjeral-Thomas MBBS, MRCP …

[HTML][HTML] Informing the risk of kidney transplantation versus remaining on the waitlist in the coronavirus disease 2019 era

…, E Sandhu, C Smith, R Storey, A Tanna… - Kidney international …, 2021 - Elsevier
Introduction There are limited data pertaining to comparative outcomes of remaining on
dialysis versus kidney transplantation as the threat of coronavirus disease 2019 (COVID-19) …